The company focuses on advancing new product concepts through the 505(b)(2) process to early clinical proof of principle followed by asset (project) sale. Achelios has a semi-virtual model that utilizes its experienced team and on-call external pharmaceutical experts and partners to control costs and advance projects. This allows the company to tailor project needs with the right level of expertise and key opinion leaders, enabling the development of pharmaceutical products designed to reformulate non-steroidal anti-inflammatory drug molecules as topically delivered medications. The company's technology focuses on therapeutic compound development for the treatment of sprains, migraine prophylaxis, osteoarthritis, and strains by decreasing side effects and improving efficacy.